The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques
Open accessAbstract
mRNA vaccines are rapidly emerging as a powerful platform for infectious diseases because they are well tolerated, immunogenic, and scalable and are built on precise but adaptable antigen design. We show that two immunizations of modified non-replicating mRNA encoding influenza H10 hemagglutinin (HA) and encapsulated in lipid nanoparticles (LNP) induce protective HA inhibition titers and H10-specific CD4 + T cell responses after intramuscular or intradermal delivery in rhesus macaques. Administration of LNP/mRNA induced rapid and local infiltration of neutrophils, monocytes, and dendritic cells (DCs) to the site of administration and the draining lymph nodes (LNs). While these cells efficiently internalized LNP, mainly monocytes and DCs translated the mRNA and upregulated key co-stimulatory receptors (CD80 and CD86). This coincided with upregulation of type I IFN-inducible genes, including MX1 and CXCL10. The innate immune activation was transient and resulted in priming of H10-specific CD4 + T cells exclusively in the vaccine-draining LNs. Collectively, this demonstrates that mRNA-based vaccines induce type-I IFN-polarized innate immunity and, when combined with antigen production by antigen-presenting cells, lead to generation of potent vaccine-specific responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More robust germinal centre responses are consistent with antigen dissemination to multiple lymph nodes and the self-adjuvating characteristics of the mRNA–lipid nanoparticle vaccine platform compared to nonadjuvanted inactivated vaccines used for seasonal influenza virus vaccination7,20,21.”
From SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses (2021) · cites this paper as [21]
In the citing paper
“and enhances delivery to the cytosol of antigen-presenting cells (Liang et al., 2017, Lindsay et al., 2019).”
From mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability (2021) · cites this paper as Liang et al., 2017
In the citing paper
“Vaccine targeted cell types (see Mode of action), such as dendritic cells (DCs) and monocytes, highly express LDL receptors and other scavenger receptors [41]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [41]
In the citing paper
“Similar to the more classical vaccine approaches, the COVID-19 mRNA vaccines are injected in the muscle, where they trigger localized and transient inflammation that recruits different immune cells to the injection site (Fig. 3 ) [11,41]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [41]
In the citing paper
“According to mechanistic studies on the fate of mRNA LNPs in rhesus monkeys, primarily monocytes and DC subsets translate the mRNA, likely involving ApoE dependent endocytosis [41]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [41]
In the citing paper
“In addition, they could detect mature, mRNA-transfected APCs in the draining LNs.”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [127]
In the citing paper
“Although all of these cell types were able to internalize mRNA LNPs, only monocytes and myeloid DCs showed high translation of the mRNA.”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [127]
In the citing paper
“With respect to the resulting immune response, they showed that i.d.delivery resulted in an earlier activation of skin DCs and a more efficient migration to draining LNs, as well as a prolonged antigen availability at the injection site.”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [127]
In the citing paper
“For both administration routes, they could show a rapid recruitment of neutrophils, monocytes and different DC subsets to the injection site (skin or muscle).”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [127]
In the citing paper
“Together, this resulted in a superior immunogenicity compared to i.m. delivery, as i.d.injection resulted in the highest antibody titers and CD4 + T cell activation.”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,927
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Skin immune sentinels in health and disease
Nestle, F. O., Meglio, P. D., Qin, J., & Nickoloff, B. J. (2009) · Nature reviews. Immunology · doi:10.1038/nri2622 · Cited by 1,529
Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors
Cros, J. F., Cagnard, N., Woollard, K. J., Patey, N., Zhang, S., Sénéchal, B., Puel, A., Biswas, S. K., Moshous, D., Pïcard, C., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.012 · Cited by 1,320
Jongbloed, S. L., Kassianos, A. J., McDonald, K. J., Clark, G. J., Ju, X., Angel, C. E., Chen, C. J., Dunbar, P. R., Wadley, R. B., Jeet, V., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20092140 · Cited by 1,019
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 384
Nanoformulations: A Valuable Tool in the Therapy of Viral Diseases Attacking Humans and Animals
Jampílek, J., & Kráľová, K. (2019) · Springer eBooks · doi:10.1007/978-3-030-29768-8_7 · Cited by 20
Fernandes, R. S., Burle-Caldas, G. D. A., Sérgio, S. A. R., Bráz, A. F., Leite, N. P. D. S., Pereira, M. C. A., Silva, J. D. O., Hojo-Souza, N. S., de Oliveira, B., Fernandes, A. P., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03201-8 · Cited by 20
Microfluidic and Turbulent Mixing for mRNA LNP Vaccines
Ahl, P. L. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091148 · Cited by 20
Immunology of RNA-based vaccines: The critical interplay between inflammation and expression
Tregoning, J. S., Wang, Z., Sridhar, S., Shattock, R. J., & DeRosa, F. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.011 · Cited by 21
Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment
Kang, X., Mita, N., Zhou, L., Wu, S., Yue, Z., Babu, R. J., & Chen, P. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091228 · Cited by 20
Tan, N. J. H., Tay, K. X. J., Wong, S. B. J., & Nga, M. E. (2021) · Diagnostic Cytopathology · doi:10.1002/dc.24863 · Cited by 19
Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy
Kim, H. J., Seo, S. K., & Park, H. Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.029 · Cited by 18
Liang, Z., Bao, H., Yao, Z., Li, M., Chen, C., Zhang, L., Wang, H., Guo, Y., Ma, Y., Yang, X., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122569 · Cited by 18
The mRNA vaccine platform for veterinary species
Fazel, F., Doost, J. S., Raj, S., Boodhoo, N., Karimi, K., & Sharif, S. (2024) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2024.110803 · Cited by 19
RNA vaccines: The dawn of a new age for tuberculosis?
Li, J., Liu, D., Li, X., Wei, J., Du, W., Zhao, A., & Xu, M. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2469333 · Cited by 19
Platelet and immune signature associated with a rapid response to the BNT162b2 mRNA COVID‐19 vaccine
Flego, D., Cesaroni, S., Romiti, G. F., Corica, B., Marrapodi, R., Scafa, N., Maiorca, F., Lombardi, L., Pallucci, D., Pulcinelli, F. M., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15648 · Cited by 18
Think like a Virus: Toward Improving Nanovaccine Development against SARS-CoV-2
Mohamed, N. A., Abou-Saleh, H., Mohamed, H. A., Al-Ghouti, M. A., Crovella, S., & Zupin, L. (2022) · Viruses · doi:10.3390/v14071553 · Cited by 17
Development of innate and adaptive immunity to RSV in young children
Parsons, E. L., Kim, J. S., & Malloy, A. M. W. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104824 · Cited by 17
Advancement in the development of mRNA ‐based vaccines for respiratory viruses
Troncoso‐Bravo, T., Ramírez, M. A., Loaiza, R. A., Román-Cárdenas, C., Papazisis, G., Garrido, D. A., González, P. A., Bueno, S. M., & Kalergis, A. M. (2024) · Immunology · doi:10.1111/imm.13844 · Cited by 20
Edwards, D. K., & Carfı́, A. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102214 · Cited by 18
Hushmandi, K., Fooladi, A. A. I., Reiter, R. J., Farahani, N., Liang, L., Aref, A. R., Nabavi, N., Alimohammadi, M., Liu, L., & Sethi, G. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00662-3 · Cited by 16
Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines
Rudra, A., Gupta, A., Reed, K., Deik, A., Min, J., Mansour, H. M. A., Nguyen, Q. T. C., Danko, A., Hu, Y., Berger, A., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02044-6 · Cited by 18
Rood, J. E., Yoon, S. K., Heard, M. K., Carro, S. D., Hedgepeth, E. J., O'Mara, M. E., Hogan, M. J., Le, N., Muramatsu, H., Lam, K., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68080-x · Cited by 17
Toyama, K., Eto, T., Takazawa, K., Shimizu, S., Nakayama, T., Furihata, K., Sogawa, Y., Kumazaki, M., Jonai, N., Matsunaga, S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.012 · Cited by 18
Advances and Strategies in Enhancing mRNA Cancer Vaccines
Zhang, M., Chen, S., Hu, H.-J., Ong, Y., & Ni, Q. (2025) · Advanced Materials · doi:10.1002/adma.202509880 · Cited by 17
Electromechanical convective drug delivery devices for overcoming diffusion barriers
Park, J., Ghanim, R. W., Rahematpura, A., Gerage, C., & Abramson, A. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.008 · Cited by 15
Diverse priming outcomes under conditions of very rare precursor B cells
Madden, P. J., Marina-Zárate, E., Rodrigues, K. A., Steichen, J. M., Shil, M., Ni, K., Michaels, K. K., Maiorino, L., Upadhyay, A. A., Saha, S., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.003 · Cited by 15
Kahn, B., Apostolidis, S. A., Bhatt, V., Greenplate, A. R., Kallish, S., LaCava, A. F., Lucas, A., Meyer, N. J., Negoianu, D., Ogdie, A., et al. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000578 · Cited by 15
Inoué, S., Mizoguchi, I., Sonoda, J., Sakamoto, E., Katahira, Y., Hasegawa, H., Watanabe, A., Furusaka, Y., Xu, M., Yoneto, T., et al. (2022) · Cancer Science · doi:10.1111/cas.15542 · Cited by 15
Effects of various mRNA-LNP vaccine doses on neuroinflammation in BALB/c mice
Kirshina, A., Kazakova, A., Kolosova, E., Имашева, Е. А., Vasileva, O., Zaborova, O. V., Terenin, I. M., Muslimov, A., & Reshetnikov, V. V. (2022) · Вестник Российского государственного медицинского университета · doi:10.24075/brsmu.2022.068 · Cited by 15
Kikuchi-Fujimoto disease can present as delayed lymphadenopathy after COVID-19 vaccination
Kashiwada, T., Saito, Y., Terasaki, Y., Shirakura, Y., Shinbu, K., Tanaka, T., Tanaka, Y., Seike, M., & Gemma, A. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2071080 · Cited by 14
Translation of in vitro-transcribed RNA therapeutics
von der Haar, T., Mulroney, T. E., Hedayioglu, F. D. L., Kurusamy, S., Rust, M., Lilley, K. S., Thaventhiran, J. E. D., Willis, A. E., & Smales, C. M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1128067 · Cited by 14
Yadav, N., Vishwakarma, P., Khatri, R., Siddqui, G., Awasthi, A., Ahmed, S., & Samal, S. (2021) · Microbes and Infection · doi:10.1016/j.micinf.2021.104843 · Cited by 14
Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2
Lin, G., Yan, H., Sun, J., Zhao, J., & Zhang, Y. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.021 · Cited by 14
Kordyukova, L. V., & Shanko, A. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921070026 · Cited by 13
Considerations on the Design of Lipid-based mRNA Vaccines Against Cancer
Meulewaeter, S., Zhang, Y., Wadhwa, A., Fox, K., Lentacker, I., Harder, K. W., Cullis, P. R., Smedt, S. C. D., Cheng, M. H. Y., & Verbeke, R. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168385 · Cited by 13
Multicomponent Lipid Nanoparticles for RNA Transfection
Gretskaya, N., Akimov, M., Andreev, D. E., Zalygin, A., Belitskaya, Е. D., Зинченко, Г. Н., Fomina-Ageeva, E. V., Mikhalyov, I. I., Vodovozova, E. L., & Безуглов, В. В. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041289 · Cited by 14
mRNA therapeutics beyond vaccines: dosing precision challenges and clinical translation framework
Niazi, S. K. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00159e · Cited by 12
Lipid Nanoparticle: Beyond Delivery Vehicle—Unveiling Its Immunological Adjuvant Potential
Amor, N. P., Guo, K., Zhang, S., Xia, J., Yang, Y., & Lin, A. (2025) · The FASEB Journal · doi:10.1096/fj.202500622r · Cited by 12
Self-citationClinical Development of mRNA Vaccines: Challenges and Opportunities
August, A., Brito, L., Paris, R., & Zaks, T. Z. (2022) · Current topics in microbiology and immunology · doi:10.1007/82_2022_259 · Cited by 12
Self-citationThe lymphatic system and COVID-19 vaccines
Miyasaka, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1041025 · Cited by 12
COVID-19 vaccines and a perspective on Africa
Mantovani, A., Rescigno, M., Forni, G., Tognon, F., Putoto, G., Ictho, J., & Lochoro, P. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.01.005 · Cited by 12
Takano, T., Morikawa, M., Adachi, Y., Kabasawa, K., Sax, N., Moriayma, S., Sun, L., Isogawa, M., Nishiyama, A., Onodera, T., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3956654 · Cited by 12
Next-generation vaccines against bacterial pathogens: mRNA and beyond
Chen, H., Gu, Y., Song, L., & Si, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1709794 · Cited by 13
Szebeni, J., & Koller, Á. (2025) · Vaccines · doi:10.3390/vaccines13080855 · Cited by 11
La nueva generación de vacunas de ARN mensajero (ARNm) frente a la gripe
Reina, J. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.07.009 · Cited by 11
Fongaro, B., Campara, B., Moscatiello, G. Y., Luigi, A. D., Panzeri, D., Sironi, L., Bigini, P., Carretta, G., Miolo, G., Pasut, G., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123319 · Cited by 12
Marcos-Villar, L., Perdiguero, B., Anthiya, S., Borrajo, M. L., Lou, G., Franceschini, L., Esteban, I., Sánchez‐Cordón, P. J., Zamora, C., Sorzano, C. Ó. S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00838-8 · Cited by 11
Mohri, K., Miyazaki, T., Warashina, S., Takahashi, M., Ren, Q., Iida, R., Wada, Y., Maeda, K., Watanabe, Y., Suzuki, Y., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c14143 · Cited by 10
Engstrand, O., Joas, G., Miranda, M. C., Yan, X., Lenart, K., Cerveira, R. A., Reinhardt, A., & Loré, K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102588 · Cited by 10
Self-citationPromising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine
Barati, S., Ghoflchi, S., Hosseinzadeh, P., Pouramini, S., Hosseini, H., & Jalili‐Nik, M. (2025) · Cancer Medicine · doi:10.1002/cam4.71187 · Cited by 11
Akahata, W., Komori, M., Morey, A. L., Quiñones-Molina, A. A., Hood, J. B., Fofana, J., Romero, L., Peters, E., Webber, J. D., Meeks, T., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adz2276 · Cited by 10
Phospholipids tailor mRNA lipid nanoparticle delivery efficacy and immunogenicity
Shi, L. D., Su, K., Lin, L., Yan, X., Zhang, X., He, S., Fu, X., Sheng, X., Kong, N., & Liu, S. (2026) · Materials Today · doi:10.1016/j.mattod.2026.01.004 · Cited by 10
Ugwu, O. P.-C., Okon, M. B., Ogenyi, F. C., Ugwu, J. N., & Ugwu, C. N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1758902 · Cited by 10
Wong, S., Oshansky, C. M., Guo, X.-Z. J., Ralston, J., Wood, T., Reynolds, G. E., Seeds, R., Jelley, L., Waite, B., Jeevan, T., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100237 · Cited by 10
Musa, H. H., & Musa, T. H. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2135927 · Cited by 11
The new generation of messenger RNA (mRNA) vaccines against influenza
Reina, J. (2022) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2022.07.006 · Cited by 10
mRNA Vaccination: An Outlook on Innate Sensing and Adaptive Immune Responses
Doost, J. S., Fazel, F., Boodhoo, N., & Sharif, S. (2024) · Viruses · doi:10.3390/v16091404 · Cited by 9
Dasti, L., Giampiccolo, S., Pettinà, E., Fiandaca, G., Zangani, N., Leonardelli, L., Hedayioglu, F. D. L., Campanile, E., & Marchetti, L. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70041 · Cited by 9
Zhen, Z., Lin, X., Darji, M., Dan, N., Ranjbar, S., & Lü, X. (2025) · AAPS Open · doi:10.1186/s41120-025-00125-3 · Cited by 9
Apaydin, D. C., Sadhnani, G., Carlaw, T., Renziehausen, J., Lizunova, E., Filor, V., Hiller, A. L., Brumhard, S., Halim, V., Brüning, U., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.01.001 · Cited by 10
Li, M., Liu, M., Song, S., Zhao, R., Xie, Y., Liu, J., Xu, L., Ma, X., Song, M., Zhou, J., et al. (2024) · Vaccines · doi:10.3390/vaccines12030300 · Cited by 9
Literature Mining and Mechanistic Graphical Modelling to Improve mRNA Vaccine Platforms
Leonardelli, L., Lofano, G., Selvaggio, G., Parolo, S., Giampiccolo, S., Tomasoni, D., Domenici, E., Priami, C., Song, H., Medini, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.738388 · Cited by 9
Vaccine Boosting CAR-T Cell Therapy: Current and Future Strategies
Ansah, E. O., Baah, A., & Agyenim, E. B. (2023) · Advances in Cell and Gene Therapy · doi:10.1155/2023/8030440 · Cited by 9
Bettini, E., Chudnovskiy, A., Protti, G., Nakandakari-Higa, S., Ceglia, S., Castaño, D., Chiu, J. E., Muramatsu, H., Mdluli, T., Ábrahám, E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.17.594726 · Cited by 10
Scholaert, M., Peries, M., Braun, E. J., Martin, J.-C., Serhan, N., Loste, A., Bruner, A., Basso, L., Chaput, B., Merle, E., et al. (2024) · Allergy · doi:10.1111/all.16273 · Cited by 8
Clinical Analysis and Applications of mRNA Vaccines in Infectious Diseases and Cancer Treatment
Ankrah, P. K., Ilesanmi, A. O., Akinyemi, A. O., Lasehinde, V., Adurosakin, O. E., & Ajayi, O. H. (2023) · Cureus · doi:10.7759/cureus.46354 · Cited by 8
Ding, X., Zhou, Y., He, J., Zhao, J., & Li, J. (2024) · Vaccines · doi:10.3390/vaccines12040432 · Cited by 8
Imaging the early fate of mRNA vaccines
Ols, S., & Loré, K. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0399-y · Cited by 8
Self-citationToyonaga, H., Arai, K., Zhang, M., Cheng, L., & Tanaka, H. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102592 · Cited by 7
Xie, K., Zhu, L., Duan, M., Fu, Y. W., Wang, H., Shen, Y., Li, Y., Wang, R., Jiang, Z., Chen, S., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2519823123 · Cited by 8
Neoantigens in cancer immunoediting: from mechanisms to personalized vaccines in breast cancer
Zeng, S., Li, W., Zeng, W., & Sun, L. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1733549 · Cited by 7
Miliotou, Α. N., Foltopoulou, P. F., Ingendoh‐Tsakmakidis, A., Tsiftsoglou, A. S., Vizirianakis, I. S., Pappas, I. S., & Papadopoulou, L. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010286 · Cited by 7
COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine
Wong, L.-A., Yap, C. G., Jahan, N. K., & Pillai, N. (2022) · OALib · doi:10.4236/oalib.1108624 · Cited by 8
Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019
Lutz, H., Popowski, K. D., Dinh, P., & Cheng, K. (2020) · Advanced NanoBiomed Research · doi:10.1002/anbr.202000063 · Cited by 7
Modified mRNA-Based Vaccines Against Coronavirus Disease 2019
Wang, A. Y. L. (2022) · Cell Transplantation · doi:10.1177/09636897221090259 · Cited by 7
A mRNA-LNP vaccine against Dengue Virus elicits robust, serotype-specific immunity
Wollner, C. J., Richner, M., Hassert, M. A., Pinto, A. K., Brien, J. D., & Richner, J. M. (2021) · doi:10.1101/2021.01.05.425517 · Cited by 6
Sethi, S. K., Bradley, C. E., Bialkowski, L., Pang, Y. Y., Thompson, C. D., Schiller, J. T., & Çuburu, N. (2025) · npj Vaccines · doi:10.1038/s41541-025-01131-y · Cited by 6
Immunological mechanisms of mRNA vaccines for infectious diseases
Locci, M., & Pardi, N. (2026) · Nature · doi:10.1038/s41586-026-10599-0 · Cited by 6
Jang, E.-J., Xayaheuang, S., Hwang, J. Y., Kim, Y., Lee, K., Choi, S.-T., Kwak, H. W., Nam, J., Kim, K., Yoon, B., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2495607 · Cited by 7
Soluble SARS-CoV-2 Spike glycoprotein: considering some potential pathogenic effects
Azzarone, B. G., Landolina, N., Mariotti, F. R., Moretta, L., & Maggi, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616106 · Cited by 6
Path to Success and Future Impact of Nucleic Acid Vaccines: DNA and mRNA
Ulmer, J. B., & Liu, M. A. (2021) · Molecular Frontiers Journal · doi:10.1142/s2529732521400022 · Cited by 6
Progress in vaccine development for infectious diseases—a Keystone Symposia report
Cable, J., Graham, B. S., Koup, R. A., Seder, R. A., Karikó, K., Pardi, N., Barouch, D. H., Sharma, B., Rauch, S., Nachbagauer, R., et al. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14975 · Cited by 8
Self-citationSun, H., Cao, X., Sumayya, Ma, Y., Li, H., Han, W., & Qu, L. (2024) · BMC Veterinary Research · doi:10.1186/s12917-024-03890-7 · Cited by 6
Controlling Protein Expression by Delivery of RNA Therapeutics Using Lipid Nanoparticles
Lin, P. J. C., & Tam, Y. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00009-5 · Cited by 6
Xiao, Y., Xu, H., Guo, W. Q., Zhao, Y., Luo, Y., Wang, M., He, Z., Ding, Z., Liu, J., Deng, L., et al. (2020) · Molecular Biomedicine · doi:10.1186/s43556-020-00017-w · Cited by 6
The rise of mRNA therapeutic vaccines
Du, J., Fan, Z., Huang, J., Li, Z., Hu, H., & Li, Y. (2025) · RSC Pharmaceutics · doi:10.1039/d4pm00309h · Cited by 5
Song, Z., Jiao, L., Wang, D., Qiu, Y., Miao, J., Zhu, T., Yu, R., Wang, Z., Zhou, Y., Cai, T., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117036 · Cited by 5
Emerging lipid nanoparticle systems capable of efficient intramuscular RNA delivery
Raza, A., Zhang, R., Lu, R., Wen, J., & Wu, W. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2555507 · Cited by 7
Next‐Generation Nonviral Vectors for mRNA Vaccine Delivery
Chen, M., Hu, X., & Liu, S. (2022) · Macromolecular Chemistry and Physics · doi:10.1002/macp.202100443 · Cited by 5
Pallás, R. M. (2024) · Vacunas (English Edition) · doi:10.1016/j.vacune.2024.05.002 · Cited by 5
Orrù, V., Steri, M., Cucca, F., & Fiorillo, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714461 · Cited by 5
Preparation, characterization, and stability of lipid nanoparticles including unsaturated lipids
Park, Y., & Park, J.-W. (2023) · Tenside Surfactants Detergents · doi:10.1515/tsd-2023-2544 · Cited by 5
SARS-CoV-2 mRNA vaccine is re-adenylated in vivo , enhancing antigen production and immune responsePreprint
Krawczyk, P. S., Gewartowska, O., Mazur, M., Orzeł, W., Matylla-Kulińska, K., Jeleń, S., Turowski, P., Śpiewla, T., Tarkowski, B., Tudek, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.01.518149 · Cited by 5
Development of mRNA Cancer Vaccines: Delivery Strategies and Immunogenicity Optimization
Ali, A. (2025) · Current Medical Science · doi:10.1007/s11596-025-00127-y · Cited by 4
Strategies for HIV-1 suppression through key genes and cell therapy
Sorokina, A. V., Anchakova, E., & Dashinimaev, E. B. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1259995 · Cited by 4
Modulation of B cell receptor activation by antibody competition
He, Y., Guo, Z., & Vahey, M. D. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115944 · Cited by 3
Styles, T. M., Akhtar, A., Gu, C., Neumann, G., Muramatsu, H., McPartlan, J. S., Talukder, P., Gratz, D., Stokdyk, K., Turner, H. L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102369 · Cited by 3
Duran, T., Çine, N., Karaselek, M. A., Gül, N., Küççüktürk, S., Hatipoğlu, D., Ateş, M. B., Çalışkan, Ü., & Koçak, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-08142-8 · Cited by 3
Fredericq, L., Hamouda, A. E. I., Zhong, Z., Ginderachter, J. A. V., Geest, B. G. D., & Laoui, D. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114799 · Cited by 3
Qiao, P., Yu, J., Li, C., Chen, B., & Wang, Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114820 · Cited by 3
Breakthroughs in mRNA vaccines and innovations in drug development
Wei, L., & Xue, Y. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1058 · Cited by 3
Seo, M., Lee, M., Seo, Y.-J., Kim, J., Oh, J., Kim, J., Cho, Y., Chang, J., & Kim, H. (2025) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2025.02.023 · Cited by 3
Improving the Efficacy of Cancer mRNA Vaccines
Kirtane, A. R., & Traverso, G. (2025) · The Cancer Journal · doi:10.1097/ppo.0000000000000764 · Cited by 3
Zhai, Y., Ku, M., Yang, K., Patil, A., Prabhala, P., He, L., Man, Y., Rahman, M., Menon, K., Spörri, S. B., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116416 · Cited by 3
Metadata
- Authors
- Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., Brito, L. A., Salter, H., Ciaramella, G., & Loré, K.
- Affiliations
- Karolinska Institutet (SE)
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Loré, Karin
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 25
- Issue
- 12
- Pages
- 2635-2647
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC5768558
- OpenAlex
- W2745973480
- Cited by
- 395
- References
- 50
- Citations by year
- 2026: 33 · 2025: 69 · 2024: 60 · 2023: 53 · 2022: 66 · 2021: 62 · 2020: 23 · 2019: 20 · 2018: 7 · 2017: 2
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Swedish Research Council (2015-02608)
- Fernström Foundation
- Swedish Society of Medicine
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Keywords
- mRNA vaccines, lipid nanoparticles, antigen-presenting cells, dendritic cells, monocytes, CD4+ T cell responses, type I interferon, MX1, CXCL10, intradermal vaccination, intramuscular vaccination, innate immune activation, rhesus monkeys
- MeSH terms
- Animals, Antigen-Presenting Cells, Immunization, Influenza Vaccines, Injections, Intradermal, Lymph Nodes, Macaca mulatta, Phenotype, RNA, Messenger, T-Lymphocytes, Vaccines, Gene Expression, Immunophenotyping, Cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
